Clinical Advancements in the Management of Familial Hypercholesterolemia

This special symposium was held at the 2013 NLA Annual Scientific Sessions this past May in Las Vegas, NV with audio and slide highlights captured for additional viewing. This activity defines HoFH and discusses the marked cardiovascular risk associated with this diagnosis. Please join our panel of expert faculty as they discuss the most efficacious options for screening and genetic testing to identify hidden, high-risk patients, and the most current therapeutic options for FH patients who are unable to reach their target LDL-C levels on statin therapy alone.